ArticleTranslational psychiatry2013
Use of functional imaging across clinical phases in CNS drug development.
Article in Translational psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- White matter microstructural alterations in Huntington's disease: a systematic review of diffusion imaging findings.Brain imaging and behavior · 2026Pooled it
- Pooled it
- Changes in cerebral function parameters in persons with HIV with symptoms of insomnia switching from dolutegravir- to bictegravir-based antiretroviral therapy.Journal of neurovirology · 2025Trial
- Effects of Ketamine and Midazolam on Simultaneous EEG/fMRI Data During Working Memory Processes.Brain topography · 2021Trial
- A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.Nature medicine · 2020Trial
- Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.International journal of geriatric psychiatry · 2014Trial
- Enhancing Blood-Brain Barrier Penetration Prediction by Machine Learning-Based Integration of Novel and Existing, In Silico and Experimental Molecular Parameters from a Standardized Database.Journal of chemical information and modeling · 2025Article
- High hopes? Precision psychedelic addiction medicine.Frontiers in psychiatry · 2025Review
- Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.Journal of Huntington's disease · 2024Review
- Pharmacological manipulation of neurotransmitter activity induces disparate effects on cerebral blood flow and resting-state fluctuations.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Experimental Medicine Approaches in Early-Phase CNS Drug Development.Advances in neurobiology · 2023Article
- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.Advances in neurobiology · 2023Article
- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.Advances in neurobiology · 2023Article
- The Role of fMRI in Drug Development: An Update.Advances in neurobiology · 2023Article
- Impact of Donepezil on Brain Glucose Metabolism Assessed Using [Frontiers in neuroscience · 2022Article
- Brain Imaging Biomarkers for Chronic Pain.Frontiers in neurology · 2021Review
- Positron emission tomography evaluation of oxime countermeasures in live rats using the tracer O-(2-[Annals of the New York Academy of Sciences · 2020Article
- Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures.Neurobiology of disease · 2020Review
- The Opioid Crisis and the Future of Addiction and Pain Therapeutics.The Journal of pharmacology and experimental therapeutics · 2019Review
- Response to "Treating patients rather than their functional neuroimages" (Br J Anaesth 2018; 121: 969-71).British journal of anaesthesia · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of novel brain biomarkers using nuclear magnetic resonance imaging holds potential of making central nervous system (CNS) drug development more efficient. By evaluating changes in brain function in the disease state or drug effects on brain function, the technology opens up the possibility of obtaining objective data on drug effects in the living awake brain. By providing objective data, imaging may improve the probability of success of identifying useful drugs to treat CNS diseases across all clinical phases (I-IV) of drug development. The evolution of functional imaging and the promise it holds to contribute to drug development will require the development of standards (including good imaging practice), but, if well integrated into drug development, functional imaging can define markers of CNS penetration, drug dosing and target engagement (even for drugs that are not amenable to positron emission tomography imaging) in phase I; differentiate objective measures of efficacy and side effects and responders vs non-responders in phase II, evaluate differences between placebo and drug in phase III trials and provide insights into disease modification in phase IV trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.